Sigilon Therapeutics, Inc.·4

Dec 1, 4:45 PM ET

Orfali May 4

4 · Sigilon Therapeutics, Inc. · Filed Dec 1, 2021

Insider Transaction Report

Form 4
Period: 2021-12-01
Orfali May
CHIEF MEDICAL OFFICER
Transactions
  • Award

    Stock Option (Right to Buy)

    2021-12-01+80,00080,000 total
    Exercise: $3.14Exp: 2031-11-30Common Stock (80,000 underlying)
Footnotes (1)
  • [F1]The option vests as to 25% of the underlying shares of common stock on November 29, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.

Documents

1 file
  • 4
    form4-12012021_011233.xmlPrimary